Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

In its latest CNS partnership, Biogen is doubling down on targets already in its pipeline with a gene regulation technology from Sangamo it hopes will shut down target expression altogether.

By closing off target expression, the company takes a different, possibly complementary, approach to treating Alzheimer’s disease (AD) and Parkinson’s disease, where the prevailing strategy is to block proteins from exerting their toxic effects...